How can Long COVID symptoms be counteracted?<\/h3>\n
To date, the management of <\/span>fatigue<\/span><\/i> has no clear guidelines: it ranges from simple behavioral advice to hypotheses of more invasive interventions. One of the avenues being explored is <\/span>nutraceutical supplementation<\/b>, and it is precisely in this area that at the <\/span>ASST-FBF-Sacco Hospital in Milan<\/b> a study has begun to test the efficacy of <\/span>CellFasting<\/b>, a supplement of the precursors of <\/span>glutathione<\/b>, <\/span>resveratrol<\/b> and <\/span>NAD+<\/b> developed by SoLongevity research (patented formula <\/span>GluReNAD<\/b>, read more here).<\/span><\/p>\n CellFasting – antioxidant and energizing<\/p><\/div>\n It is estimated that 66-87% of people who have had mild-to-moderate COVID do not return to their previous state of health<\/p><\/blockquote>\n The randomized, double-blind SFATICOVID<\/strong> clinical study (\u201cStudy on the relief of Fatigue Associated To Incompletely <\/em><\/span>healed COVID-19<\/em>\u201d) has just completed the enrollment of <\/span>154 patients<\/b> over 18 years of age, with a documented previous COVID-19 infection and with symptoms of asthenia lasting more than 90 days, followed at the ARCOVID outpatient clinic of the hospital’s Department of Infectious Diseases. According to the protocol, half of them will receive CellFasting and the other half a placebo for 8 weeks. <\/span><\/p>\n \u201cThe aim of the study is to understand whether supplementation can act above all on the dimension of exhaustion, which emerges as the predominant symptom,\u201d explains <\/span>Guido Cornettone<\/b>, Co-founder of SoLongevity: \u201cThe research stems from an intuition of ours, linked precisely to the difficulty of defining Long COVID, since this condition can present symptoms of illness within a normal clinical picture. A situation that is in some ways similar to chronic fatigue syndrome<\/strong>.\u201d <\/span><\/p>\n Although physiological parameters are normal, people affected by Long COVID often experience exhaustion so severe that it prevents normal activities<\/p><\/div>\n It is hypothesized that fatigue is underpinned by an imbalance of the redox state<\/b>, with consequences for the capacity to produce ATP<\/b>, the so-called \u201cenergy\u201d molecule, which is fundamental for all the energy reactions of cells. This imbalance can generate a state of chronic inflammation and neuroinflammation that may explain the neurological symptoms of Long COVID. As shown by a previous study published in Nutrients<\/i>, CellFasting is able to exert a strong antioxidant activity and to generate ATP. Preliminary results from other observational studies in Long COVID patients have also suggested considerable efficacy of CellFasting against the most common symptoms, including fatigue, brain fog and sleep disturbances. <\/p>\n The SFATICOVID clinical study will verify whether supplementation with CellFasting is able to restore the redox balance, acting on the inflammatory state and reducing the exhaustion typical of Long COVID<\/p><\/blockquote>\n At the beginning and end of the 8 weeks of treatment, an assessment of the patients’ redox state<\/b> will be carried out at the outpatient clinic and some specific functional parameters will be measured. The tests will be performed through the SoLongevity prevention services platform<\/b> (already used in some pharmacies in Milan). Validated psychometric questionnaires will also be administered, while parameters such as sleep quality, heart rate, oxygen saturation, basal temperature and perceived stress will be monitored via Fitbit<\/b>. Cognitive performance will also be assessed, particularly in relation to memory. \u201cWe want to test,\u201d concludes Cornettone, \u201cthe efficacy of CellFasting both for cognitive recovery and on the perception of fatigue.\u201d <\/p>\n","protected":false},"excerpt":{"rendered":" Conducted by SoLongevity Research in collaboration with Sacco Hospital in Milan, the study will assess in more than 150 patients the efficacy of the nutraceutical on the redox state and on the symptoms of the disease, in particular on tiredness, brain fog and sleep quality.<\/p>\n","protected":false},"author":1,"featured_media":1080,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[156,158],"tags":[164,168],"class_list":["post-40875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cellfasting","category-news-en","tag-covid-en","tag-nutraceutics"],"acf":[],"yoast_head":"\n![\"SoLongevity](\"https:\/\/solongevity.com\/wp-content\/uploads\/2022\/06\/CellFasting_2-1024x828.jpg\")
What does the clinical study by SoLongevity and Sacco Hospital in Milan involve?<\/h3>\n
What is the rationale for the study?<\/h3>\n
![\"\"](\"https:\/\/solongevity.com\/wp-content\/uploads\/2022\/11\/shutterstock_2037935936.jpg\")
What tests will the assessment be based on?<\/h3>\n